Glycophorin E Activators are a collection of chemical compounds that indirectly enhance the functional activity of Glycophorin E through various signaling pathways, contributing to erythrocyte stability and signaling. Compounds like Forskolin and Genistein indirectly elevate the protein's activity through the cAMP/PKA and tyrosine kinase inhibition pathways, respectively. Forskolin increases intracellular cAMP levels, prompting PKA activation which may lead to phosphorylation events that enhance Glycophorin E's role in erythrocyte membrane stability. Genistein, by inhibiting tyrosine kinases, reduces phosphorylation competition, potentially increasing the specific phosphorylation and functional activity of Glycophorin E. Similarly, PMA acts as a PKC activator and, along with sphingosine-1-phosphate, can influence the protein's functionality by modulating cytoskeletal dynamics and intracellular signaling related to membrane integrity.
The activity of Glycophorin E is also influenced by the modulation of intracellular calcium levels and PI3K signaling, withagents such as Thapsigargin, A23187, LY294002, and Wortmannin playing pivotal roles. Thapsigargin and A23187 increase intracellular calcium, which could activate calcium-dependent kinases and pathways that indirectly enhance Glycophorin E's structural and signaling roles. Inhibition of PI3K by LY294002 and Wortmannin may lead to altered downstream signaling, potentially favoring pathways that enhance Glycophorin E's function in erythrocyte membrane maintenance. Furthermore, the use of kinase inhibitors like Epigallocatechin gallate (EGCG) and Staurosporine may shift the phosphorylation equilibrium, indirectly promoting Glycophorin E's activity. Lastly, MEK and p38 MAPK inhibitors, U0126 and SB203580, by altering the MAPK/ERK signaling, could indirectly enhance the role of Glycophorin E in signal transduction and membrane stability, highlighting the complex regulatory network that these activators influence to augment the functionality of Glycophorin E.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate membrane proteins and potentially increase the functional activity of Glycophorin E in erythrocyte membrane stability and cell-cell interactions. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC) which is involved in the phosphorylation of various proteins. PKC-mediated phosphorylation could enhance the function of Glycophorin E in maintaining erythrocyte membrane integrity and cellular signaling. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate interacts with its receptors to activate intracellular signaling cascades, which can lead to cytoskeletal rearrangements. This may indirectly enhance the structural role of Glycophorin E in the erythrocyte membrane. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin elevates intracellular calcium levels by inhibiting the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). Increased intracellular calcium can activate calcium-dependent kinases which may indirectly enhance the activity of Glycophorin E in cellular processes. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG, a catechin found in green tea, has been shown to inhibit certain types of kinases. This alteration in kinase activity could lead to a change in phosphorylation patterns, thus potentially enhancing the role of Glycophorin E in erythrocyte function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. By inhibiting PI3K, it may affect downstream signaling pathways, potentially enhancing Glycophorin E's role in cellular signaling and membrane stability. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. Similar to LY294002, it could alter signaling pathways which in turn may enhance the activity of Glycophorin E in erythrocyte membrane maintenance. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a potent protein kinase inhibitor, could lead to selective activation of signaling pathways by inhibiting kinase-mediated negative feedback mechanisms, potentially enhancing Glycophorin E function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which could disrupt MAPK/ERK signaling. Alteration in this pathway may indirectly enhance Glycophorin E's role in signal transduction and membrane stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK. By modulating this pathway, it could potentially enhance the activity of Glycophorin E in cellular signaling and membrane integrity. | ||||||